General approach to identifying potential targets for cancer imaging by integrated bioinformatics analysis of publicly available genomic profiles

Molecular Imaging

Volumn 10, Issue 2, 2011, Pages 123-134

  Yang, Yongliang ^a   Adelstein, S James ^a   Kassis, Amin I ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL FUNCTIONS; BIOINFORMATICS ANALYSIS; BIOMEDICAL RESEARCH; CANCER IMAGING; CELL SURFACES; CELLULAR FUNCTION; CONTROL TESTS; DISEASE PROCESS; DRUG DEVELOPMENT; FOLATE RECEPTOR; GENERAL APPROACH; GENES ENCODING; GENOMIC PROFILES; HUMAN CANCER; HUMAN DISEASE; HUMAN TUMORS; INTERACTION NETWORKS; KNOWLEDGE BASE; LITERATURE MINING; MEMBRANE-BOUND PROTEINS; MICROARRAY DATABASE; MOLECULAR IMAGING; PATHWAY ANALYSIS; PROSTATE CANCERS; PROSTATE-SPECIFIC MEMBRANE ANTIGENS; SUB-NETWORK; THERAPEUTIC TARGETS; TUMOR CELLS; UROKINASE PLASMINOGEN;

BIOINFORMATICS; CELL MEMBRANES; DIAGNOSIS; ENZYME INHIBITION; GENES; GROWTH KINETICS; KNOWLEDGE BASED SYSTEMS; MEDICAL IMAGING; TUMORS;

DISEASES;

TUMOR PROTEIN;

ACCESS TO INFORMATION; ARTICLE; BIOLOGY; CELL PROLIFERATION; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE REGULATORY NETWORK; GENETIC DATABASE; GENETICS; HUMAN; HUMAN GENOME; METABOLISM; METHODOLOGY; NEOPLASM; PATHOLOGY; PROTEIN BINDING;

ACCESS TO INFORMATION; CELL PROLIFERATION; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; DIAGNOSTIC IMAGING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE REGULATORY NETWORKS; GENOME, HUMAN; HUMANS; NEOPLASM PROTEINS; NEOPLASMS; PROTEIN BINDING;

EID: 79953249014     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2010.00024     Document Type: Article

References (44)

1. Britz-Cunningham SH, Adelstein SJ. Molecular targeting with radionuclides: State of the science. J Nucl Med 2003;44:1945-61. (Pubitemid 40022141)
2. Weissleder R. Molecular imaging in cancer. Science 2006;312: 1168-71. (Pubitemid 43801133)
3. Liotta LA, Steeg PS, Stetler-Stevenson WG. Cancer metastasis and angiogenesis: An imbalance of positive and negative regulation. Cell 1991;64:327-36. (Pubitemid 121001258)
4. Humblet V, Lapidus R, Williams LR, et al. High-affinity nearinfrared fluorescent small-molecule contrast agents for in vivo imaging of prostate-specific membrane antigen. Mol Imaging 2005;4:448-62. (Pubitemid 43143785)
5. Pospisil P, Wang K, Al Aowad AF, et al. Computational modeling and experimental evaluation of a novel prodrug for targeting the extracellular space of prostate tumors. Cancer Res 2007;67:2197-205. (Pubitemid 46424239)
6. Pospisil P, Iyer LK, Adelstein SJ, Kassis AI. A combined approach to data mining of textual and structured data to identify cancerrelated targets. BMC Bioinformatics 2006;7:354.
7. Yang Y, Adelstein SJ, Kassis AI. Target discovery from data mining approaches. Drug Discov Today 2009;14:147-54.
8. Rhodes DR, Chinnaiyan AM. Integrated analysis of the cancer transcriptome. Nat Genet 2005;37 Suppl:S31-7.
9. Kim B, Lee HJ, Choi HY, et al. Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res 2007;67:7431-8. (Pubitemid 47206573)
10. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, et al. Oncomine 3.0: Genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia 2007;9:166-80.
11. Yang Y, Pospisil P, Iyer LK, et al. Integrated genomic data mining for discovery of potential blood-borne biomarkers for early diagnosis of cancer. PLoS ONE 2008;3:e3661.
12. Storey JD, Tibshirani R. Statistical significance for genomewide studies. Proc Natl Acad Sci U S A 2003;100:9440-5. (Pubitemid 37033947)
13. Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin receptor imaging in the localization of endocrine tumors. N Engl J Med 1990;323:1246-9. (Pubitemid 20366530)
14. Kumar U, Grigorakis SI, Watt HL, et al. Somatostatin receptors in primary human breast cancer: Quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005;92:175-86. (Pubitemid 40933583)
15. Anderson CJ, Pajeau TS, Edwards WB, et al. In vitro and in vivo evaluation of copper-64-octreotide conjugates. J Nucl Med 1995; 36:2315-25.
16. Okarvi SM. Peptide-based radiopharmaceuticals and cytotoxic conjugates: Potential tools against cancer. Cancer Treat Rev 2008; 34:13-26. (Pubitemid 351168607)
17. Becker A, Hessenius C, Licha K, et al. Receptor-targeted optical imaging of tumors with near-infrared fluorescent ligands. Nat Biotechnol 2001;19:327-31. (Pubitemid 32275340)
18. Robinson MK, Doss M, Shaller C, et al. Quantitative immunopositron emission tomography imaging of HER2-positive tumor xenografts with an iodine-124 labeled anti-HER2 diabody. Cancer Res 2005;65:1471-8. (Pubitemid 40270176)
19. Loo C, Hirsch L, Lee MH, et al. Gold nanoshell bioconjugates for molecular imaging in living cells. Opt Lett 2005;30:1012-4. (Pubitemid 40749266)
20. Bhattacharyya S, Wang S, Reinecke D, et al. Synthesis and evaluation of near-infrared (NIR) dye-herceptin conjugates as photoacoustic computed tomography (PCT) probes for HER2 expression in breast cancer. Bioconjug Chem 2008;19:1186-93. (Pubitemid 351874940)
21. Sipkins DA, Cheresh DA, Kazemi MR, et al. Detection of tumor angiogenesis in vivo by avb3-targeted magnetic resonance imaging. Nat Med 1998;4:623-6. (Pubitemid 28237365)
22. Beer AJ, Haubner R, Sarbia M, et al. Positron emission tomography using [18F]galacto-RGD identifies the level of integrin alpha(v)beta3 expression in man. Clin Cancer Res 2006;12:3942-9. (Pubitemid 44078079)
23. Ellegala DB, Leong-Poi H, Carpenter JE, et al. Imaging tumor angiogenesis with contrast ultrasound and microbubbles targeted to avb3. Circulation 2003;108:336-41. (Pubitemid 36899026)
24. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 2004; 304:1497-500. (Pubitemid 38720929)
25. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. (Pubitemid 38944402)
26. Pal A, Glekas A, Doubrovin M, et al. Molecular imaging of EGFR kinase activity in tumors with 124I-labeled small molecular tracer and positron emission tomography. Mol Imaging Biol 2006;8:262-77. (Pubitemid 44446020)
27. Li W, Li F, Huang Q, et al. Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. Cancer Res 2008;68:4990-7.
28. Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M. MUC1 and cancer. Biochim Biophys Acta 1999. 301-13. (Pubitemid 29435996)
29. Singh R, Bandyopadhyay D. MUC1: A target molecule for cancer therapy. Cancer Biol Ther 2007;6:481-6. (Pubitemid 47328319)
30. Salouti M, Rajabi H, Babaei MH, Rasaee MJ. Breast tumor targeting with (99m)Tc-HYNIC-PR81 complex as a new biologic radiopharmaceutical. Nucl Med Biol 2008;35:763-8.
31. Schülke N, Varlamova OA, Donovan GP, et al. The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy. Proc Natl Acad Sci U S A 2003;100:12590-5. (Pubitemid 37339943)
32. Banerjee SR, Foss CA, Castanares M, et al. Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem 2008; 51:4504-17.
33. Torres-Rosado A, O'Shea KS, Tsuji A, et al. Hepsin, a putative cellsurface serine protease, is required for mammalian cell growth. Proc Natl Acad Sci U S A 1993;90:7181-5. (Pubitemid 23222413)
34. Tanimoto H, Yan Y, Clarke J, et al. Hepsin, a cell surface serine protease identified in hepatoma cells, is overexpressed in ovarian cancer. Cancer Res 1997;57:2884-7. (Pubitemid 27315033)
35. Kelly KA, Setlur SR, Ross R, et al. Detection of early prostate cancer using a hepsin-targeted imaging agent. Cancer Res 2008;68:2286-91. (Pubitemid 351521802)
36. Duffy MJ. The urokinase plasminogen activator system: Role in malignancy. Curr Pharm Des 2004;10:39-49. (Pubitemid 38072742)
37. Law B, Curino A, Bugge TH, et al. Design, synthesis, and characterization of urokinase plasminogen-activator-sensitive near-infrared reporter. Chem Biol 2004;11:99-106. (Pubitemid 38203994)
38. Li ZB,Niu G, Wang H, et al. Imaging of urokinase-type plasminogen activator receptor expression using a 64Cu-labeled linear peptide antagonist by microPET. Clin Cancer Res 2008;14:4758-66.
39. Toffoli G, Cernigoi C, Russo A, et al. Overexpression of folate binding protein in ovarian cancers. Int J Cancer 1997;74: 193-8. (Pubitemid 27234510)
40. Ke CY, Mathias CJ, Green MA. Folate-receptor-targeted radionuclide imaging agents. Adv Drug Deliv Rev 2004;56:1143-60. (Pubitemid 38499700)
41. Bredel M, Scholtens DM, Harsh GR, et al. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009;302: 261-75.
42. Seaton A, Scullin P, Maxwell PJ, et al. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis 2008;29:1148-56. (Pubitemid 351958693)
43. Waugh DJJ, Wilson C. The interleukin-8 pathway in cancer. Clin Cancer Res 2008;14:6735-41.
44. Engl T, Relja B, Marian D, et al. CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006;8:290-301.